Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutrition 21

This article was originally published in The Tan Sheet

Executive Summary

AMBI shareholders approve name change to Nutrition 21, effective immediately, firm announces. Trading symbol on NASDAQ becomes NXXI effective March 9. "Nutrition 21 is a name that underscores our expertise in nutrition and our science-based approach to the market," Chromax maker says. New name applies to all company operations, including ingredient sales and consumer products business (1"The Tan Sheet" Jan. 22, In Brief)

You may also be interested in...



AMBI name change

Company will change its name to Nutrition 21 following shareholder approval in March. Ticker symbol also will change on NASDAQ from AMBI to NXXI, company says Jan. 17. "The Nutrition 21 name is used by AMBI's nutrition products subsidiary, and will in the future apply to all company operations, including ingredient sales and the consumer products business," Chromax and Selenomax maker says. AMBI has said it plans to move away from finished product sales to focus more heavily on supplying ingredients and licensing products to other companies (1"The Tan Sheet" Nov. 20, 2000, p. 10)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel